


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


### Listing of Claims:

1. (Currently amended) A compound for modulating kinase activity of Formula I,



or a pharmaceutically acceptable salt thereof, wherein,


Ar is selected from the following formulae



wherein Ar is substituted with  $-X$  and  $-Y-L-Z$ , in an ortho relationship to each other, and said Ar is optionally substituted with up to four  $R^1$ ;

each  $R^1$  is independently selected from  $-H$ , halogen,  $-CN$ ,  $-NO_2$ ,  $-OR^3$ ,  $-N(R^3)R^3$ ,  $-S(O)_{0-2}R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^3$ ,  $-N(R^3)SO_2R^3$ ,  $-N(R^3)C(O)R^3$ ,  $-N(R^3)CO_2R^3$ ,  $-C(O)R^3$ ,  $-OC(O)R^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

$X$  is selected from the following formulae.



wherein  $R^{4a}$  is  $-C(O)N(R^3)R^3$ ;

$n = 1$  or  $2$ ;

p = 0 or 1;

q is 1 to 3;

M is  $-\text{OR}^3$  or  $-\text{N}(\text{R}^3)\text{R}^4$ ;

~~each  $\text{R}^2$  is independently selected from -H, halogen, oxo, -CN,  $\text{NH}_2$ ,  $\text{NO}_2$ ,  $\text{OR}^3$ ,  $\text{N}(\text{R}^3)\text{R}^3$ ,  $\text{N}(\text{R}^3)\text{R}^3$ ,  $\text{S}(\text{O})_{0-2}\text{R}^3$ ,  $\text{SO}_2\text{N}(\text{R}^3)\text{R}^3$ ,  $\text{CO}_2\text{R}^3$ ,  $\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^3$ ,  $\text{N}(\text{R}^3)\text{SO}_2\text{R}^3$ ,  $\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$ ,  $\text{N}(\text{R}^3)\text{CO}_2\text{R}^3$ ,  $\text{N}(\text{R}^3)\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^3$ ,  $\text{C}(\text{O})\text{R}^3$ ,  $\text{OC}(\text{O})\text{R}^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;~~

~~two of  $\text{R}^2$ , together with the atoms to which they are attached, can form an optionally substituted three to seven-membered ring system;~~


each  $\text{R}^2$  is independently selected from -H, haloalkyl,  $-\text{C}_{1-6}\text{alkyl}-\text{N}(\text{R}^3)\text{R}^3$ ,  $-\text{C}_{1-6}\text{alkyl}-\text{OR}^3$ ,  $-\text{C}_{1-6}\text{alkyl}-\text{CO}_2\text{R}^3$ , and  $-\text{C}_{1-6}\text{alkyl}-\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^3$ ;

each  $\text{R}^3$  is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or


two of  $\text{R}^3$ , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;

each  $\text{R}^4$  is independently selected from  $\text{R}^3$ ,  $-\text{SO}_2\text{R}^3$ ,  $-\text{SO}_2\text{N}(\text{R}^3)\text{R}^3$ ,  $-\text{CO}_2\text{R}^3$ ,  $-\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^3$ , and  $-\text{C}(\text{O})\text{R}^3$ ;

~~-Y-L-Z is selected from the following formulae;~~



Y-L-Z is selected from the following formulae,



wherein g is zero to two; ~~D is selected from  $C(R^5)(R^5)$ ,  $O$ ,  $S(O)_{0-2}$ , and  $N(R^4)$~~ ; Q is  $=N$  or  $-C(R^5)-$ ; T is selected from absent,  $-N(R^3)-$ ,  $-S-$  and  $-O-$ ; and each methylene between Y and T is optionally substituted; provided that when both Y and T are heteroatoms then g must be two;

~~Y is selected from  $-CH_2-$ ,  $O$ ,  $S(O)_{0-2}$ ,  $N(R^3)-$ , and absent;~~


Y is  $-O-$  or optionally substituted  $-CH_2-$ ;

$R^5$  is selected from  $-H$ , halogen,  $-CN$ ,  $-NO_2$ ,  $-OR^3$ ,  $-N(R^3)R^4$ ,  $-S(O)_{0-2}R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R$ ,  $-N(R^3)SO_2R^3$ ,  $-N(R^3)C(O)R^3$ ,  $-N(R^3)CO_2R^3$ ,  $-C(O)R^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and


optionally two of  $R^5$ , together with the atoms to which they are attached, form a second ring system fused with said five- to seven-membered ring system, said second ring system substituted with zero to four of  $R^5$ .

2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)

10. (Canceled)
11. (Canceled)
12. (Currently amended) The compound according to claim ~~11~~ 1, wherein g is one or two.
13. (Original) The compound according to claim 12, wherein each  $R^5$  is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>4</sup>, -S(O)<sub>0.2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)CO<sub>2</sub>R<sup>3</sup>, -C(O)R<sup>3</sup>, and optionally substituted lower alkyl.
14. (Original) The compound according to claim 13, wherein -Y-L-Z is selected from the following formulae.



15. (Currently amended) The compound according to claim 14, having formula **III**,



**III**

wherein J is N or CH, and B is =N- or =C(R<sup>5</sup>)-

16. (Original) The compound according to claim 15, wherein R<sup>3a</sup> is selected from optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl.
17. (Original) The compound according to claim 16, wherein R<sup>3a</sup> is selected from optionally substituted aryl and optionally substituted heteroaryl.


18. (Original) The compound according to claim 17, wherein  $R^{3a}$  is optionally substituted phenyl.
19. (Original) The compound according to claim 18, wherein said optionally substituted phenyl is substituted with at least one of halogen,  $-CN$ ,  $-CF_3$ ,  $-NH_2$ ,  $-NO_2$ ,  $-OR^3$ ,  $-N(R^3)R^3$ ,  $-S(O)_{0-2}R^3$ ,  $-SO_2N(R^3)R^3$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^3$ ,  $-N(R^3)SO_2R^3$ ,  $-N(R^3)C(O)R^3$ ,  $-N(R^3)CO_2R^3$ ,  $-C(O)R^3$ , optionally substituted lower alkyl, and optionally substituted aryl.
20. (Original) The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one trifluoromethyl group.
21. (Original) The compound according to claim 20, wherein said optionally substituted phenyl group is substituted with at least two trifluoromethyl groups
22. (Original) The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one lower alkyl group.
23. (Original) The compound according to claim 19, wherein  $R^{3b}$  is  $-H$ .
24. (Original) The compound according to claim 23, wherein  $R^{4b}$  is selected from  $R^3$ ,  $-H$ ,  $-CO_2R^3$ ,  $-C(O)N(R^3)R^4$ , and  $-C(O)R^3$ .
25. (Canceled)
26. (Canceled)
27. (Original) The compound according to claim 24, wherein Ar is according to the formula below.



28. (Original) The compound according to claim 24, wherein Ar is according to the formula below.




29. (Canceled)
30. (Previously presented) A compound for modulating kinase activity of Formula IV,



IV

or a pharmaceutically acceptable salt thereof, wherein,

Ar is selected from the following formulae:



each  $R^1$  is independently selected from -H, halogen, -CN, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>3</sup>, -S(O)<sub>0-2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>, -N(R<sup>3</sup>)CO<sub>2</sub>R<sup>3</sup>, -C(O)R<sup>3</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

optionally two of  $R^1$ , together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of  $R^1$ ;

each  $R^2$  is independently selected from -H, halogen, oxo, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>3</sup>, -N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)R<sup>5</sup>, -S(O)<sub>0-2</sub>R<sup>3</sup>, -SO<sub>2</sub>N(R<sup>3</sup>)R<sup>3</sup>, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>3</sup>, -N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, -N(R<sup>3</sup>)C(O)R<sup>3</sup>,

$-\text{N}(\text{R}^3)\text{CO}_2\text{R}^3$ ,  $-\text{N}(\text{R}^3)\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^3$ ,  $-\text{C}(\text{O})\text{R}^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclalkyl;

two of  $\text{R}^2$ , together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;

each  $\text{R}^3$  is independently selected from  $-\text{H}$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclalkyl; or

two of  $\text{R}^3$ , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocycl ring, said optionally substituted five- to seven-membered heterocycl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;

each  $\text{R}^4$  is independently selected from  $\text{R}^3$ ,  $-\text{SO}_2\text{R}^3$ ,  $-\text{SO}_2\text{N}(\text{R}^3)\text{R}^3$ ,  $-\text{CO}_2\text{R}^3$ ,  $-\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}^3$ , and  $-\text{C}(\text{O})\text{R}^3$ ;

Y is selected from optionally substituted  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{S}-$ , and  $-\text{N}(\text{R}^3)-$ ;

L is selected from optionally substituted  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{N}(\text{R}^3)-$  and absent;

provided that Y and L are not both heteroatoms;

B is  $=\text{N}-$  or  $=\text{C}(\text{H})-$ ;

at each instance,  $\text{R}^5$  and  $\text{R}^6$  are independently selected from  $-\text{H}$ , halogen,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{OR}^3$ ,  $-\text{N}(\text{R}^3)\text{R}^4$ ,  $-\text{S}(\text{O})_{0-2}\text{R}^3$ ,  $-\text{SO}_2\text{N}(\text{R}^3)\text{R}^3$ ,  $-\text{CO}_2\text{R}^3$ ,  $-\text{C}(\text{O})\text{N}(\text{R}^3)\text{R}$ ,  $-\text{N}(\text{R}^3)\text{SO}_2\text{R}^3$ ,  $-\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$ ,  $-\text{N}(\text{R}^3)\text{CO}_2\text{R}^3$ ,  $-\text{C}(\text{O})\text{R}^3$ , optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclalkyl; and

optionally two of  $\text{R}^5$ , together with the atoms to which they are attached, form a ring system fused with the ring containing B according to formula IV, said ring system substituted with zero to two additional of  $\text{R}^5$ .

31. (Original) The compound according to claim 30, wherein Y is -O- and L is optionally substituted -CH<sub>2</sub>-.
32. (Original) The compound according to claim 31, wherein at least one of R<sup>6</sup> is optionally substituted lower alkyl.
33. (Original) The compound according to claim 32, wherein said at least one optionally substituted lower alkyl is *meta*- to the piperazine urea function as depicted in formula IV.
34. (Original) The compound according to claim 33, wherein R<sup>4a</sup> is selected from R<sup>3</sup>, -H, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>4</sup>, and -C(O)R<sup>3</sup>.
35. (Original) The compound according to claim 34, wherein R<sup>4a</sup> is selected from -H, -CO<sub>2</sub>R<sup>3</sup>, -C(O)N(R<sup>3</sup>)R<sup>4</sup>, and -C(O)R<sup>3</sup>.
36. (Original) The compound according to claim 35, wherein -Y-L- is -OCH<sub>2</sub>-.
37. (Canceled)
38. (Canceled)
39. (Original) The compound according to claim 36, wherein Ar is according to the formula below.



40. (Original) The compound according to claim 36, wherein Ar is according to the formula below.



41. (Canceled)
42. A compound selected from Table 4.

**Table 4**

**Table 4**

|     |                                                                                                                   |  |
|-----|-------------------------------------------------------------------------------------------------------------------|--|
| 97  | N-[3,5-bis(trifluoromethyl)phenyl]-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide            |  |
| 103 | N-(4-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide                            |  |
| 105 | N-(3-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide                            |  |
| 142 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide |  |
| 144 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide                  |  |
| 161 | methyl [4-({[2-(4-{{(3-ethylphenyl)amino}carbonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]carbamate   |  |

**Table 4**

|     |                                                                                                                       |  |
|-----|-----------------------------------------------------------------------------------------------------------------------|--|
| 164 | methyl 4-({2-(4-({(3-bromophenyl)amino}carbonyl)piperazin-1-yl)pyridin-3-yl}oxy)methylpyridin-2-yl}carbamate          |  |
| 165 | methyl 4-({2-(4-({(3-(methyloxy)phenyl)amino}carbonyl)piperazin-1-yl)pyridin-3-yl}oxy)methylpyridin-2-yl}carbamate    |  |
| 166 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-(methyloxy)phenyl]piperazine-1-carboxamide                |  |
| 167 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-(1-methylethyl)phenyl]piperazine-1-carboxamide            |  |
| 168 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-[(trifluoromethyl)oxy]phenyl]piperazine-1-carboxamide     |  |
| 169 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[2-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide |  |







**Table 4**

|     |                                                                                                                                                   |  |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 170 | N-(3-ethylphenyl)-4-[3-({[2-({[(3-ethylphenyl)amino]carbonyl}amino)pyridin-4-yl]methyl}oxy)pyridin-2-yl]piperazine-1-carboxamide                  |  |
| 171 | N-(3-ethylphenyl)-4-(3-{{[2-{{[4-methylpiperazin-1-yl]acetyl]amino}pyridin-4-yl]methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide                  |  |
| 173 | N-[3,5-bis(trifluoromethyl)phenyl]-4-(3-{{[2-{{[4-methylpiperazin-1-yl]acetyl]amino}pyridin-4-yl]methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide |  |
| 174 | 4-(3-{{[2-aminopyrimidin-4-yl]methyl}oxy}pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide                                      |  |
| 175 | 4-[3-({[2-(acetilamino)pyridin-4-yl]methyl}oxy)pyridin-2-yl]-N-(3-ethylphenyl)piperazine-1-carboxamide                                            |  |

**Table 4**

|     |                                                                                                                       |  |
|-----|-----------------------------------------------------------------------------------------------------------------------|--|
| 176 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethyl-4-fluorophenyl)piperazine-1-carboxamide            |  |
| 177 | 2-[4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)piperazin-1-yl]-N-[3,5-bis(trifluoromethyl)phenyl]acetamide |  |
| 178 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-phenylpiperazine-1-carboxamide                              |  |
| 179 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-chloro-5-ethylphenyl)piperazine-1-carboxamide            |  |
| 180 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(5-ethyl-2-fluorophenyl)piperazine-1-carboxamide            |  |
| 181 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-bromo-5-ethylphenyl)piperazine-1-carboxamide             |  |






**Table 4**

|     |                                                                                                                                 |                                                                                     |
|-----|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 182 | 2-(4-methylpiperazin-1-yl)ethyl [4-({[2-ethylphenyl]amino}carbonyl)piperazin-1-yl]pyridin-3-yl]oxy)methylpyridin-2-yl]carbamate |    |
| 183 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-chlorophenyl)piperazine-1-carboxamide                               |    |
| 184 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-bromophenyl)piperazine-1-carboxamide                                |    |
| 185 | N-[4-({[2-(4-acetyl)piperazin-1-yl]pyridin-3-yl]oxy)methylpyridin-2-yl]-2-(4-methylpiperazin-1-yl)acetamide                     |    |
| 186 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-fluorophenyl)piperazine-1-carboxamide                               |   |
| 187 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(4-fluorophenyl)piperazine-1-carboxamide                               |  |








**Table 4**

|     |                                                                                                                          |  |
|-----|--------------------------------------------------------------------------------------------------------------------------|--|
| 188 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy};pyridin-2-yl)-N-(2-fluorophenyl)piperazine-1-carboxamide                       |  |
| 189 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy};pyridin-2-yl)-N-(3,5-diethylphenyl)piperazine-1-carboxamide                    |  |
| 190 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy};-5-bromopyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide                |  |
| 191 | N-methyl-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy};pyridin-2-yl)piperazine-1-carboxamide |  |
| 192 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy};pyridin-2-yl)-N-[2-chloro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide   |  |
| 193 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy};pyridin-2-yl)-N-(5-chloro-2-fluorophenyl)piperazine-1-carboxamide              |  |
| 194 | 4-(3-{{(2-amino-5-bromopyrimidin-4-yl)methyl}oxy};-5-bromopyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide        |  |

**Table 4**

|     |                                                                                                                                      |                                                                                    |
|-----|--------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| 195 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[2-fluoro-3-(trifluoromethyl)phenyl]piperazine-1-carboxamide                |   |
| 196 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide                |   |
| 197 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3,5-dichlorophenyl)piperazine-1-carboxamide                                |   |
| 198 | N-(3-chloro-5-ethylphenyl)-4-(3-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide |   |
| 199 | N-(5-ethyl-2-fluorophenyl)-4-(3-{{(2-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide                   |  |

**Table 4**

|     |                                                                                                                                        |                                                                                    |
|-----|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| 200 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-ethyl-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide                   |   |
| 204 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-methylpiperazine-1-carboxamide                                                |   |
| 205 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-ethylpiperazine-1-carboxamide                                                 |   |
| 206 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-cyclohexylpiperazine-1-carboxamide                                            |   |
| 207 | 4-({[2-(4-acetyl)piperazin-1-yl]pyridin-3-yl}oxy)methylpyrimidin-2-amine                                                               |   |
| 208 | 4-({[2-(4-propanoyl)piperazin-1-yl]pyridin-3-yl}oxy)methylpyrimidin-2-amine                                                            |   |
| 209 | N-(3-cyclopropylphenyl)-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide |  |






**Table 4**

|     |                                                                                                                                                       |  |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 210 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-cyclopropylphenyl)piperazine-1-carboxamide                                                |  |
| 211 | N-[2-fluoro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide |  |
| 212 | N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide |  |
| 213 | N-(3,5-dichlorophenyl)-4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide                 |  |
| 214 | 4-(3-{{(2-{{(4-methylpiperazin-1-yl)acetyl}amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide          |  |

**Table 4**

|     |                                                                                                                                       |  |
|-----|---------------------------------------------------------------------------------------------------------------------------------------|--|
| 216 | 4-(3-{{[1-(2-aminopyrimidin-4-yl)ethyl]oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide                   |  |
| 219 | 4-[[({2-[4-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperazin-1-yl]pyridin-3-yl}oxy)methyl]pyrimidin-2-amine                             |  |
| 220 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(2-methylpropyl)piperazine-1-carboxamide                                    |  |
| 226 | N-(3,5-diethylphenyl)-4-(3-{{[(2-{{(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl}oxy)methyl]pyridin-2-yl}piperazine-1-carboxamide |  |
| 227 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-methylpyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide                            |  |
| 228 | 4-(3-{{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-methylpyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide           |  |

**Table 4**

|     |                                                                                                                                                                 |                                                                                    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| 233 | N-[3-chloro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide          |   |
| 235 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-chloro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide                                           |   |
| 237 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}-6-chloropyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide                                                       |   |
| 243 | N-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-4-(3-{{(2-{{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl}oxy}pyridin-2-yl)piperazine-1-carboxamide |   |
| 244 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}-6-chloropyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide                                      |  |

**Table 4**

|     |                                                                                                                                |  |
|-----|--------------------------------------------------------------------------------------------------------------------------------|--|
| 245 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide                               |  |
| 246 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}-6-chloropyridin-2-yl)-N-(5-ethyl-2-fluorophenyl)piperazine-1-carboxamide             |  |
| 247 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-(3-ethyl-5-fluorophenyl)piperazine-1-carboxamide                      |  |
| 249 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide |  |
| 250 | 4-(3-{{(2-aminopyrimidin-4-yl)methyl}oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]-N-methylpiperazine-1-carboxamide     |  |

43. (Previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

44. (Canceled)

45. (Canceled)

46. (Canceled)

47. (Canceled)

48. (Canceled)
49. (Canceled)
50. (Canceled)
51. (Canceled)
52. (Canceled)
53. (Canceled)
54. (Canceled)
55. (Canceled)
56. (Canceled)
57. (Canceled)